U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease; INVOKANA® is now the only oral diabetes treatment approved to reduce the

Media coverage

• Title	U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease; INVOKANA® is now the only oral diabetes treatment approved to reduce the
  Media name/outlet	PR Newswire
  Country	United States
  Date	10/30/18
  Persons	Ralph A Defronzo

• Title	U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease; INVOKANA® is now the only oral diabetes treatment approved to reduce the
  Media name/outlet	PR Newswire
  Country	United States
  Date	10/30/18
  Persons	Ralph A Defronzo